Going to the negative: genomics for optimized medical prescription

[1]  E. Vassos,et al.  Polygenic risk scores: from research tools to clinical instruments , 2020, Genome Medicine.

[2]  Niklas Blomberg,et al.  Connecting data, tools and people across Europe: ELIXIR’s response to the COVID-19 pandemic , 2020, European Journal of Human Genetics.

[3]  A. Motsinger-Reif,et al.  Fibrate pharmacogenomics: expanding past the genome. , 2020, Pharmacogenomics.

[4]  G. Gibson,et al.  The greater inflammatory pathway—high clinical potential by innovative predictive, preventive, and personalized medical approach , 2019, EPMA Journal.

[5]  Janice M. Fullerton,et al.  Polygenic risk scores in psychiatry: Will they be useful for clinicians? , 2019, F1000Research.

[6]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[7]  G. Watts,et al.  Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and , 2017, Circulation.

[8]  Judy H. Cho,et al.  Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study , 2017, The Lancet.

[9]  R. Owens,et al.  Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.

[10]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[11]  Olle Melander,et al.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.

[12]  John Abraham,et al.  Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions , 2010 .

[13]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[14]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.